Advances in surgical techniques and laparoscopic instruments have resulted in the development of laparoscopic pancreatic surgery. Total pancreaticoduodenectomy is performed for treating benign and borderline pancreatic disease involving the whole pancreas. Here, we report a case of metastatic renal cell carcinoma in the pancreas, treated by laparoscopic pylorus-preserving total pancreaticoduodenectomy. A 59-year-old woman was diagnosed with metastatic renal cell carcinoma. Multiple metastatic lesions were found on routine follow-up. She had a history of radical video-assisted right-nephrectomy for renal cell carcinoma (conventional type, pT1) in November 2003, without any recurrence. However, in 2014, a routine health checkup revealed multiple enhancing lesions throughout the pancreas. Positron emission tomography showed a suspicious 4-cm lesion in her left thyroid. Laparoscopic pylorus-preserving total pancreaticoduodenectomy with splenectomy was performed, along with simultaneous left total thyroidectomy with central compartment node dissection for metastatic renal cell carcinomas. The total operation time was 441 min, with an estimated blood loss of 150 ml; no transfusion was administered. Her hospital stay was 12 days. The histopath report confirmed metastatic renal cell carcinoma in the pancreas and left thyroid. Based on literature reviews, we further tried to estimate the oncologic outcome of total pancreatectomy in multiple pancreatic metastasis of renal cell carcinoma. Laparoscopic pylorus-preserving total pancreaticoduodenectomy is feasible and safe, even in cases of metastatic renal cell carcinoma. (Ann Hepatobiliary Pancreat Surg 2017;21:96-100)
INTRODUCTION
Pancreatic metastases from other primary cancers are uncommon, accounting for less than 5% of pancreatic cancers. Primary cancers reported to metastasize to the pancreas include renal cell carcinoma (RCC), lung cancer, colon cancer, and breast cancer; among these, RCC is the most frequent primary cancer. 1 As pancreatic metastases of RCC are usually slow growing, with tumor-free intervals ＞10 years, they are asymptomatic in more than 50% of cases and are usually incidental findings during long-term follow-ups. 2 Although uncommon, when the primary cancer metastasizes only to the pancreas, the pancreatic resection of the isolated metastasis is proven to improve long-term patient survival. Operation: Laparoscopic total pancreatectomy combines laparoscopic pylorus-preserving pancreaticoduodenectomy and laparoscopic subtotal distal pancreatectomy with splenectomy. 4, 5 Left total thyroidectomy was performed through a 6-cm transverse skin incision on the anterior neck. The operation lasted 7 hours 21 minutes, with an estimated intraoperative blood loss of approximately 150 ml. Pathologic examination revealed multiple nodules in the pancreas, with a maximum size of 1.7 cm×1.1 cm; a 3.7-cm nodule was also found in the left thyroid. Both these nodules were consistent with RCC metastasis (Fig.   1E ).
Postoperative course: The patient's postoperative recovery was uneventful. She discharged on postoperative day 12, without complications. During five months of follow-up, there was no evidence of local recurrence or distant metastasis.
Literature review
We searched PubMed for reported cases of total pancreatectomy for multiple pancreatic metastasis of RCC, using the keywords "renal cell carcinoma" and "total pancreatectomy". A total of 30 case reports written in English, describing 50 patients, were identified. Patient demographics and presentations are listed in Table   1 . Of note, 28 patients (58.3%) had extrapancreatic multi-organ metastasis of RCC.
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The mean overall disease-specific survival of patients who underwent total pancreatectomy for multiple pancre- Fig. 2B and C) . However, anal-ysis revealed that the maximum tumor size influenced the oncologic outcome, and tumor size over 3 cm was associated with adverse oncologic outcomes in patients with total pancreatectomy for multiple pancreatic metastasis (p=0.050, Fig. 2D ).
DISCUSSION
RCC is the most frequent primary cancer metastasizing to the pancreas. Due to the long time interval between primary RCC and metastasis, 9 a long-term and meticulous follow-up is required. Literature reviewed by us showed that the median time interval between the primary RCC resection and pancreatic metastasis was 11 years, ranging from 1 to 27 years. In the present case, the multiple pancreatic metastases were identified 11 years after the initial nephrectomy for RCC. The duration to pancreatic metastasis from initial nephrectomy for RCC was not associated with negative oncologic outcomes (Fig. 2B) , suggesting that careful follow-up and proper aggressive surgical approach are important in treating multiple pancreatic metastasis of RCC.
We learnt from the current literature review that long-term survival of total pancreatectomy in patients with multiple pancreatic metastasis of RCC was 84.4 months.
Compared to oncologic outcomes following surgical resection of multiple hepatic metastasis from colorectal cancer, 18 the survival of patients who underwent total pancreatectomy for multiple pancreatic metastasis of RCC appears to be double than those who underwent hepatectomy due to liver metastasis of colon cancer, thus providing an oncologic rationale to favor aggressive surgical intervention even in multiple pancreatic metastasis. Further analysis revealed no significant survival differences with other organ involvement in RCC as well as pancreas (Fig.   2C ), supporting our approach of simultaneous thyroidectomy for thyroid metastasis of RCC.
Although kidney cancer was once considered resistant to chemotherapy and radiation therapy, 19 recent reports have shown that tyrosine kinase inhibitor-targeted therapy markedly improves the prognosis of patients with metastatic RCC. 20 In our study, metastatic RCC larger than 3 cm showed poor prognosis for total pancreatectomy (Fig.   2D ).
Our study specifically dealt with several cases of total pancreatectomy due to multiple metastasis of RCC. In addition, the literature review indicated that tumor size less than 3 cm has an adverse effect on oncologic outcomes in patients with total pancreatectomy for metastatic RCC.
However, these cases were published from 1972 to 2014 at various centers, and some important clinicopathological variables were not reported. Considering the small patient number, a larger, multi-center study is needed to investigate prognostic factors and rationales of total pancreatectomy in the relevant patient population.
